Skip to main content
SpringerLink
Log in

Febuxostat: a guide to its use in chronic hyperuricaemia

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

References

  1. Hair PI, McCormack PL, Keating GM. Febuxostat. Drugs 2008; 68(13): 1865–74

    Article  PubMed  CAS  Google Scholar 

  2. European Medicines Agency. Adenuric (febuxostat): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2008 Nov 7]

  3. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64(21): 2399–416

    Article  PubMed  CAS  Google Scholar 

  4. Wortmann RL, SchumacherJr HR. Monosodium urate deposition arthropathy part II: treatment and long-term management of patients with gout. Adv Studies Med 2005; 5(4): 183–94

    Google Scholar 

  5. Becker MA, SchumacherJr HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005 Mar; 52(3): 916–23

    Article  PubMed  CAS  Google Scholar 

  6. Becker MA, SchumacherJr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. N Engl J Med 2005 Dec 8; 353(23): 2450–61

    Article  PubMed  CAS  Google Scholar 

  7. Schumacher HR, Wortmann R, Becker M, et al. Long-term safety and efficacy of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in subjects with hyperuricemia and gout [abstract no. SAT0282]. Ann Rheum Dis 2005 Jul; 64Suppl. 3: 498

    Google Scholar 

  8. Becker MA, Schumacher R, Wortmann R, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patients [abstract no. 803]. Arthritis Rheum 2004 Sep; 50(9 Suppl.): S336

    Google Scholar 

  9. Schumacher HR, Becker MA, Wortmann RL, et al. The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension study [abstract no. OP0130]. Ann Rheum Dis 2006 Jul; 65Suppl. II: 93

    Google Scholar 

  10. SchumacherJr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricaemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008 Oct 30; 59(ll): 1540–8

    Article  PubMed  CAS  Google Scholar 

  11. Becker MA, Schumacher HR, Wortmann RL, et al. The long-term clinical benefits of febuxostat vs allopurinol in subjects with gout: interim analysis of the EXCEL trial, an ongoing phase 3, open-label extension study [abstract no. FRI0483]. Ann Rheum Dis 2006 Jul; 65Suppl. II: 431

    Google Scholar 

  12. Becker MA, SchumacherJr HR, MacDonald PA, et al. Urate-lowering therapy (febuxostat or allopurinol) in subjects with gout interim results from the Febuxostat Comparative Extension Long-term Study (EXCEL) [abstract no. 757]. Arthritis Rheum 2007 Sep; 56(9 Suppl.): S322

    Google Scholar 

  13. Wortmann RL, Becker MA, Schumacher Jr HR, et al. Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trial [abstract no. 1592]. Arthritis Rheum 2006 Sep; 54(9 Suppl.): S642

    Google Scholar 

  14. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 56. London: BMJ Publishing Group Ltd and RPS Publishing, 2008 Sep

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Febuxostat: a guide to its use in chronic hyperuricaemia. Drugs Ther. Perspect 25, 1–4 (2009). https://doi.org/10.2165/0042310-200925020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925020-00001

Search

Navigation